Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Steroid minimization immunosuppression regimens after primary renal transplantation
2004-005055-33Phase 4Terminated
- Sponsor
- Barts Health NHS Trust
- Start
- Feb 2005
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of daclizumab, mycophenolate mofetil, tacrolimus, sirolimus and corticosteroids in kidney transplant immunosuppression (3 arms), sponsored by Barts Health NHS Trust. Primary endpoints: Incidence or avoidance of corticosteroid use, Acute rejection episodes at 6 months and 1 more. Started Feb 2005; status: terminated.
02
Drugs
daclizumabmycophenolate mofetiltacrolimussirolimuscorticosteroids
03
Conditions
kidney transplant immunosuppression
Beyond the preview
Go deeper on 2004-005055-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005055-33.